Cephalon Signs Option Agreement for ImmuPharma’s First-in-class Lupus Drug

By Helen Scrutton

Pharma Deals Review: Vol 2008 Issue 102 (Table of Contents)

Published: 25 Nov-2008

DOI: 10.3833/pdr.v2008.i102.105     ISSN: 1756-7874

Section: Licensing



Cephalon has paid US$15 M upfront to obtain an option for an exclusive, worldwide licence to ImmuPharma’s Phase IIb lupus product, Lupuzor™...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details